ZDHHC4 and glioblastoma: Taken together, GSK3β palmitoylation medicated by ZDHHC4 could decrease p-Ser9 and increase p-Tyr216 for GSK3β, leading to activate the EZH2/STAT3 axis to promote GSC tumorigenicity and ultimately enhance TMZ resistance in GBM (Fig. 7).